

آشنایی با Pubmed



فاطمه صادقی غیاثی
مرکز پزشکی مبتنی بر شواهد



National Library of Medicine
National Center for Biotechnology Information

Log in

PubMed.gov

Search PubMed

Search

Advanced

PubMed® comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

Feedback

سوال

آیا پلاسما در درمان بیماری کرونا نقش مؤثری دارد؟

PICO

P (Problem/Patient): Covid-19 ; coronavirus disease 2019 ; SARS-CoV-2 ;

I (Intervention): Plasma ; convalescent plasma ; plasma transfusion ; CPT ;

C (Comparison):

O (Outcome): Treatment ; Therapy ;

روش اول

PubMed.gov

covid-19 and plasma



Search

Advanced

PubMed® comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.



covid-19 and plasma



Search

[Advanced](#) [Create alert](#) [Create RSS](#)

[User Guide](#)

Save

Email

Send to

Sorted by: Best match

Display options

MY NCBI FILTERS

824 results

RESULTS BY YEAR



TEXT AVAILABILITY



Abstract



Free full text



1

Cite

Share

Deployment of convalescent **plasma** for the prevention and treatment of **COVID-19**.

Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, van Buskirk C, Grossman BJ, Joyner M, Henderson JP, Pekosz A, Lau B, Wesolowski A, Katz L, Shan H, Auwaerter PG, Thomas D, Sullivan DJ, Paneth N, Gehrie E, Spitalnik S, Hod EA, Pollack L, Nicholson WT, Pirofski LA, Bailey JA, Tobian AA. *J Clin Invest*. 2020 Jun 1;130(6):2757-2765. doi: 10.1172/JCI138745.

PMID: 32254064 [Free article.](#) [Review.](#)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of **coronavirus disease 2019 (COVID-19)**, has spurred a global health crisis. To date, there are no proven options for ...



2

Collecting and evaluating convalescent **plasma** for **COVID-19** treatment: why and how?

روش دوم

PubMed.gov

(covid-19 or coronavirus or SARS-CoV-2) and (Plasma or convalescent plasma or CPT)



Search

Advanced

PubMed® comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

Save

Email

Send to

Sorted by: Best match

Display options

MY NCBI FILTERS



1,170 results

RESULTS BY YEAR



TEXT AVAILABILITY

- ☐ Abstract
- ☐ Free full text
- ☐ Full text

ARTICLE ATTRIBUTE

Did you mean *(covid-19 or coronavirusfor SARS-CoV-2) and (plasma or convalescent plasma for cpt)* (824 results)?



Collecting and evaluating **convalescent plasma** for **COVID-19** treatment: why and how?

1

Cite

Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Vox Sang. 2020 Apr 2. doi: 10.1111/vox.12926. Online ahead of print.

Share

PMID: 32240545 Review.

Plasma provided by **COVID-19 convalescent** patients may provide therapeutic relief as the number of **COVID-19** cases escalates steeply worldwide. ...Identifying, collecting, qualifying and preparing **plasma** from **convalescent** pati ...



Deployment of **convalescent plasma** for the prevention and treatment of **COVID-19**.

2

Cite

Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, van Buskirk C, Grossman BJ, Joyner M, Henderson JP, Pekosz A, Lau B, Wesolowski A, Katz L, Shan H, Auwaerter PG, Thomas D, Sullivan DJ,

Advanced Search

NIH National Library of Medicine
National Center for Biotechnology Information

PubMed Advanced Search Builder

PubMed.gov
[User Guide](#)

Add terms to the query box

All Fields  Enter a search term

ADD 
[Show Index](#)

Query box

Enter / edit your search query here

Search 

History and Search Details

 Download  Delete

[nlm.nih.gov](#) **Search** **Actions** **Details** **Query** **Results** **Time**

PubMed Advanced Search Builder

PubMed.gov

User Guide

Add terms to the query box

All Fields

Pharmacological Action

Publication Type

Publisher

Secondary Source ID

Subject - Personal Name

Supplementary Concept

Text Word

Title

Title/Abstract

Transliterated Title

Volume

Enter a search term

ADD

Add with AND

Add with OR

Add with NOT

انتخاب فیلد جستجوی کلیدواژه

انتخاب یکی از عملگرهای بولین برای ترکیب کلیدواژه ها

you use PubMed your recent searches will appear here.

Add terms to the query box

All Fields

Enter a search term

ADD

جستجو و نمایش نتایج جستجو

Show Index

Query box

Enter / edit your search query here

Search

Add to History

Query box

Enter / edit your search query here

Add to History

اضافه کردن استراتژی و نتایج جستجو
در باکس history

Add terms to the query box

Title/Abstract ▾

Enter a search term

✕

ADD ▾

Show Index

Query box

Enter / edit your search query here

Add to History ▾

History and Search Details

Download Delete

Search	Actions	Details	Query	Results	Time
#1	...	>	Search: (((covid-19) OR (coronavirus 2019)) OR (SARS-CoV-2))) AND (plasma[Title/Abstract])	807	09:55:19

Query box

(((covid-19) OR (coronavirus 2019)) OR (SARS-CoV-2))) AND (plasma[Title/Abstract])

×

Add to History ▾

History and Search Details

Download Delete

Search	Actions	Details	Query	Results	Time
#1	⋮		(((covid-19) OR (coronavirus 2019)) OR (SARS-CoV-2))) AND (plasma[Title/Abstract])	807	09:55:19

Showing 1 to 1 of 1

- Add with AND
- Add with OR
- Add with NOT
- Delete
- Create alert

نتایج جستجو



(covid-19 or coronavirus 2019 or SARS-Cov-2) and plasma



Search

[Advanced](#) [Create alert](#) [Create RSS](#)

[User Guide](#)

Save

Email

Send to


Sorted by: Best match

Display options

MY NCBI FILTERS

833 results

RESULTS BY YEAR



TEXT AVAILABILITY

- ☐ Abstract
- ☐ Free full text
- ☐ Full text

ARTICLE ATTRIBUTE



1

Cite

Share

Antibody responses to **SARS-CoV-2** in patients of novel **coronavirus** disease **2019**.

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N, Zhang Z.

Clin Infect Dis. 2020 Mar 28;ciaa344. doi: 10.1093/cid/ciaa344. Online ahead of print.

PMID: 32221519 [Free PMC article](#).

METHODS: A total of 173 patients with **SARS-CoV-2** infection were enrolled. Their serial **plasma** samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against **SARS-CoV-2**. ...CONCLUSION ...



2

Cite

Share

Inhibition of **SARS-CoV-2** (previously **2019-nCoV**) infection by a highly potent pan-**coronavirus** fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L. Cell Res. 2020 Apr;30(4):343-355. doi: 10.1038/s41422-020-0305-x. Epub 2020 Mar 30.

833 results

Save citations to file

Selection: All results on this page

Format: Summary (text)

Summary (text)

PubMed

PMID

Abstract (text)

CSV

833 results

Save

Email

Send to

Sorted by: Best match

Display options

833 results

Email citations

Subject: (covid-19 or coronavirus 2019 or SARS-Cov-2) and - PubMed

To:

email@example.com

Selection:

All results on this page

Format:

Summary



I'm not a robot



reCAPTCHA
Privacy - Terms

Send email

Cancel

833 results

Save

Email

Send to

Sorted by: Best

Create

Clipboard

My Bibliography

Collections

Citation manager

Selection

Page

Cancel

Create a file for external citation management software

Selection:

All results

Create file

Cancel

Save

Email

Send to

Sorted by: Best match

Display options

833 results

Sorted by: Best match

Display options

DISPLAY OPTIONS

Format

Summary



Sort by

Summary

Abstract

PubMed

Per page

PMID

Show snippets



➤ Clin Infect Dis. 2020 Mar 28;ciaa344. doi: 10.1093/cid/ciaa344. Online ahead of print.

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Juanjuan Zhao¹, Quan Yuan^{2 3}, Haiyan Wang¹, Wei Liu^{2 3}, Xuejiao Liao¹, Yingying Su^{2 3}, Xin Wang¹, Jing Yuan⁴, Tingdong Li^{2 3}, Jinxiu Li⁵, Shen Qian¹, Congming Hong^{2 3}, Fuxiang Wang⁴, Yingxia Liu^{4 6}, Zhaoqin Wang⁶, Qing He⁶, Zhiyong Li³, Bin He^{2 3}, Tianying Zhang^{2 3}, Yang Fu⁷, Shengxiang Ge^{2 3}, Lei Liu^{1 6}, Jun Zhang^{2 3}, Ningshao Xia^{2 3}, Zheng Zhang^{1 6}

Affiliations + expand

PMID: 32221519 PMID: PMC7184337 DOI: 10.1093/cid/ciaa344

[Free PMC article](#)


Abstract

Background: The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated.

Methods: A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed.

Results: Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1%, 82.7% and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might due to the lack of blood samples at the later stage of illness. The median seroconversion time for Ab, IgM and then

RESULTS BY YEAR



فیلترها

TEXT AVAILABILITY

- ☐ Abstract
- ☐ Free full text
- ☐ Full text

ARTICLE ATTRIBUTE

- ☐ Associated data

ARTICLE TYPE

- ☐ Books and Documents
- ☐ Clinical Trial
- ☐ Meta-Analysis
- ☐ Randomized Controlled Trial
- ☐ Review
- ☐ Systematic Review


Additional filters

Reset all filters

فیلترها

Additional filters

Reset all filters



ARTICLE TYPE

SPECIES

LANGUAGE

SEX

SUBJECT

JOURNAL

AGE

- | | |
|--|--|
| ☐ Address | ☐ Journal Article |
| ☐ Autobiography | ☐ Lecture |
| ☐ Bibliography | ☐ Legal Case |
| ☐ Biography | ☐ Legislation |
| ☐ Case Reports | ☐ Letter |
| ☐ Classical Article | ☐ Multicenter Study |
| ☐ Clinical Conference | ☐ News |
| ☐ Clinical Study | ☐ Newspaper Article |
| ☐ Clinical Trial Protocol | ☐ Observational Study |
| ☐ Clinical Trial, Phase I | ☐ Observational Study, Veterinary |

Cancel

Show

Review

> Transfusion. 2020 Jun;60(6):1123-1127. doi: 10.1111/trf.15843. Epub 2020 May 12.

Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design

Paul Barone¹, Robert A DeSimone¹

Affiliations + expand

PMID: 32374891 PMCID: PMC7267607 DOI: 10.1111/trf.15843

Free PMC article

Abstract

Case series studying convalescent plasma use in the treatment of COVID-19 have been promising, but additional, high-quality studies are needed to determine the efficacy of the treatment when applied for prophylaxis, for early phases of illness, and for severe illness. Previous studies of convalescent plasma in treating other viral diseases have identified factors to consider when designing treatment protocols, including timing of administration relative to onset of illness, timing of donation relative to resolution of symptoms, severity of illness of the donor, pretransfusion serology of the recipient, and antibody titers of the donor. There are many clinical trials studying treatment of, and prophylaxis against, COVID-19 using convalescent plasma. In addition to clinical trials, the FDA also allows treatment through two other pathways: the "Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19" protocol, and emergency investigational new drug applications. The FDA also provides criteria for donation of convalescent plasma.

FULL TEXT LINKS



ACTIONS

Cite

Favorites

SHARE



PAGE NAVIGATION

< Title & authors

Abstract

Conflict of interest statement

NEXT RESULT
5 of 833

Review > Transfusion. 2020 Jun;60(6):1123-1127. doi: 10.1111/trf.15843. Epub 2020 May 12.

Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design

Paul Barone¹, Robert A DeSimone¹

Affiliations + expand

PMID: 32374891 PMCID: PMC7267607 DOI: 10.1111/trf.15843

Free PMC article

Abstract

Case series studying convalescent plasma use in the treatment of COVID-19 have been promising, but additional, high-quality studies are needed to determine the efficacy of the treatment when applied for prophylaxis, for early phases of illness, and for severe illness. Previous studies of convalescent plasma in treating other viral diseases have identified factors to consider when designing treatment protocols, including timing of administration relative to onset of illness, timing of donation relative to resolution of symptoms, severity of illness of the donor, pretransfusion serology of the recipient, and antibody titers of the donor. There are many clinical trials studying treatment of, and prophylaxis against, COVID-19 using convalescent plasma. In addition to clinical trials, the FDA also allows treatment through two other pathways: the "Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19" protocol, and emergency investigational new drug applications. The FDA also provides criteria for donation of convalescent plasma.

FULL TEXT LINKS



ACTIONS

Cite

Favorites

SHARE



PAGE NAVIGATION


< Title & authors

Abstract

Conflict of interest statement

NEXT RESULT
5 of 833

Cite



Page Navigation

Supplementary concepts

- > COVID-19
- > severe acute respiratory syndrome coronavirus

Related information

MedGen

LinkOut – more resources

Full Text Sources

Europe PubMed Central
Ovid Technologies, Inc.
PubMed Central
Wiley

Medical

MedlinePlus Health Information

PAGE NAVIGATION

Title & authors

< Abstract

Conflict of interest
statement

Similar articles

Cited by

References

Publication types


MeSH terms

Substances

Supplementary
concepts

Related information

LinkOut - more
resources



MeSH terms

- › Antibodies, Viral / blood*
- › Betacoronavirus / immunology*
- › Blood Component Transfusion / methods*
- › Clinical Trials as Topic / methods*
- › Convalescence*
- › Coronavirus Infections / immunology
- › Coronavirus Infections / therapy*
- › Coronavirus Infections / virology
- › Humans
- › Pandemics
- › Plasma / immunology*
- › Pneumonia, Viral / immunology
- › Pneumonia, Viral / therapy*
- › Pneumonia, Viral / virology
- › Research Design

Substances

- › Antibodies, Viral

PAGE NAVIGATION

Title & authors

◀ Abstract

Conflict of interest
statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Supplementary
concepts

Related information

LinkOut - more
resources

